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I n the coming months, this nation will launch alandmark study to further investigate stroke pre-vention strategies for asymptomatic patients
with high-grade carotid stenosis. The National Insti-
tute of Neurological Disorders and Stroke (NINDS)
CREST-2 (Carotid Revascularization Endarterectomy
Versus Stenting Trial-2) is a prospective multicenter
randomized comparison of state-of-the-art contem-
porary medical therapy versus elective revasculariza-
tion. Because the NINDS recognizes 2 complementary
and equally safe and effective methods of revascular-
ization—carotid stenting (CAS) and carotid endarter-
ectomy—the trial will have parallel paths comparing
each revascularization method to best medical
therapy.
The investigators have set the bar high in deﬁning
best medical therapy. They have rightly designed a
best medical therapy protocol to reﬂect an ideal
approach to medical care that all expect to become a
standard in future years. This “5 Starr” medical
regimen requires rigorous pharmacological control
and monitoring of hypertension, blood lipids, dia-
betes, and antiplatelet therapy. In addition, rigorous
protocol-driven lifestyle modiﬁcations, including
cessation of tobacco use, weight reduction, and ex-
ercise programs, will be instigated and monitored.
Needless to say, for this difﬁcult scientiﬁc
endeavor to produce meaningful results, the*Editorials published in JACC: Cardiovascular Interventions reﬂect the
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Company.revascularization arms will need to be conducted
with equal rigor.Carotid endarterectomy, in standard practice for
more than 50 years, enjoys the privilege of full reim-
bursement from the Centers for Medicare and
Medicaid Services (CMS) and operator volumes
remain adequate. Accordingly, the task of the CREST-
2 surgical management committee to qualify experi-
enced and creditable surgical operators should not
be a challenge. The opposite exists for the stenting
interventional management committee (IMC). Despite
the excellent comparative outcomes for stenting in
the CREST trial, CMS has determined not to cover this
less invasive and less traumatic alternative to carotid
endarterectomy. Accordingly, the number of stenting
operators with a creditable current experience is
“sparse.” As CREST-2 embarks on the important job
of trial site initiation, the stenting IMC is tasked
with the challenging mission of identifying operators
that will do credit to the trial with “5 Starr” stenting
outcomes.
The CREST IMC has requested prospective CREST-2
stenting operators to submit information on total
volume experience and detailed records on their last
25 consecutive cases. The challenge in identifying the
prospective “bad apple” from the safe and creditable
operator (commercial airline pilot analogy) has
proved enormously difﬁcult. How many errors are
pilots permitted before being grounded? From a sta-
tistical perspective, the number of cases submitted is
too small to make “meaningful” evaluations on event
rates in isolation.
The paper by Shishehbor et al. (1) in this issue of
JACC: Cardiovascular Interventions is both timely and
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1319helpful in guiding the CREST-2 IMC in its mission of
evaluating operator experience and outcomes. The
investigators attempted to improve our understanding
of operator-related factors on technical performance
for CAS by undertaking a comprehensive analysis of
previously reported and new metrics that might in-
ﬂuence outcomes. This well-conducted analysis of a
large cohort of operators and procedures (5,240 pa-
tients) in the U.S. Food and Drug Administration—
sponsored, prospective CHOICE (Carotid Stenting for
High Surgical-Risk Patients; Evaluating Outcomes
Through the Collection of Clinical Evidence) registry
focused on a speciﬁc combination of an embolic pro-
tection device (EPD) and stent. They excluded other
known confounding effects using the comprehensive
database of baseline factors and a multivariable logis-
tic regression analysis. High-volume experienced
operators have for many years taught that shortening
EPD dwell times may be a way of avoiding adverse
events during the carotid stent procedure. In this
study, the investigators hypothesized that the EPD
dwell time would be a measure of good technical per-
formance and a predictor of good outcomes. Cardiol-
ogists (p<0.001) alongwith operatorswith longer time
interval from ﬁrst CAS (p < 0.001) had reduced EPD
dwell times (technical performance). Increased time
interval between CAS was the only independent pre-
dictor of increased 30-day adverse events. Impor-
tantly, prolonged EPD dwell time was also associated
with 30-day adverse events.
How might the CREST-2 IMC and others evaluating
operator performance for CAS use this information?
Total experience (likely reﬂected in this analysis by
time from ﬁrst CAS) has been previously demon-
strated as a marker of low event rates, and now we
can add 2 additional metrics—the average interval
between submitted procedures and EPD dwell times.
It should come as no surprise that operators per-
forming a given procedure with frequency would be
proﬁcient at their work. But what of EPD dwell times?
From the outset of the work with the development of
EPD, it was known that the shear forces associatedwith ﬁltering blood through the micro pores of the
devices was associated with the precipitation and
adherence of ﬁbrin deposits to the ﬁlters. This
is likely a time-related (and device design-related)
phenomenon. There are numerous reports of ﬁlters
occluding during prolonged stenting procedures,
with this “ﬁbrin clogging” probably being the primary
event.
There are numerous other potential factors that
may make short EPD dwell times a measure of both
proﬁciency and safe outcomes. The cognitive skill of
the operator in understanding optimal patient selec-
tion immediately comes to mind. Even after “strug-
gling” to deploy an EPD in the tortuous, calciﬁed long
complex lesion (which should not be treated with
stenting), subsequent stent placement, dilation, and
EPD retrieval are challenging and may prolong the
EPD dwell time. In addition, the intervening increased
manipulation may be associated with increased
embolization. Then there is the facile, expeditious
technique! Experienced assistants and the experi-
enced team ready to assist with timely placement of
the stent may also play a role. Limiting contrast runs
(also a source of micro bubbles), minimizing post-
dilation of the stent (the most potent source of
embolic particles), and experience in knowing how to
interpret the post-stent angiographic result are also
reﬂected in shorter EPD dwell times.
The CREST-2 executive and IMC committees, in
collaboration with the NINDS, have approached CMS
to establish a CREST-2 registry that will facilitate the
current stenting experience of potential operators. In
addition to scrutinizing operator procedural tech-
nique and outcomes, we will now have 2 additional
metrics (frequency of procedures and EPD dwell
times) to aid us in selecting appropriate operators for
the trial.
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